NCT05837884Recruiting
Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population
Source: ClinicalTrials.gov · Last updated 11 Aug 2026
Brief summary (registry, in English)
We will seek consent from participants to use the data and biospecimens collected according study protocol to address additional research questions for MGUS, SMM, MM, and other conditions. Our overarching hypothesis is that early detection of MGUS/SMM in a high- risk population, along with the comprehensive characterization of genomic/epigenomic and microenvironmental/immune regulators of disease progression will lead to strategies that intercept disease progression and improve survival.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 20 Apr 2023
- Start date
- 5 Sept 2023
- Primary completion date
- Jun 2027
- Lead sponsor
- Tel-Aviv Sourasky Medical Center
- Diseases
- Multiple myeloma
- NCT number
- NCT05837884
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 5 Sept 2023 to the primary completion date, Jun 2027
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- • Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy.
- Persons with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia
- Female patient who have a positive serum pregnancy test during the screening period or a positive pregnancy test.
Who the study is looking for
- Must meet criteria of the high-risk population as described with one of the below criteria
- ≥ 30 years AND
- first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer.
- OR
- Age ≥ 18 years with 2 or more first- or second-degree relatives with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer '
- Voluntary written informed consent must be given with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care
Age in the registry: 30 years to - · Sex: All · Accepts healthy volunteers
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Soroka Coordinator of this site? Confirm its status | Beersheba | Israel | Recruiting |
| Rambam Healthcare Campus Coordinator of this site? Confirm its status | Haifa | Israel | Recruiting |
| Rabin Medical Center Coordinator of this site? Confirm its status | Petah Tikva | Israel | Recruiting |
| TASMC Coordinator of this site? Confirm its status | Tel Aviv | Israel | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.